Authors
Latest:
Commentary (Stanford/Ostrander): Prostate Cancer Risk Assessment ProgramBruner et al describe a model for risk assessment and genetic counseling of individuals and families at increased risk for prostate cancer. This model includes the establishment of a prostate cancer risk registry and screening clinic for unaffected
Latest:
Hypofractionation for Breast Cancer: Lessons Learned From Our Neighbors to the North and Across the PondIn this review we discuss the rationale and underlying radiobiologic concepts for hypofractionation, and review the clinical trials and ASTRO guidelines supporting hypofractionated radiation in the treatment of breast cancer.
Latest:
Hereditary Renal Tumor Syndromes and the Use of mTOR InhibitorsA 47-year-old woman with a history of drug-resistant epilepsy during childhood presented to the emergency department with sudden dyspnea and chest pain. Upon admission, her oxygen saturation was 88%.
Latest:
ACR Appropriateness Criteria® Ductal Carcinoma in SituManagement of ductal carcinoma in situ (DCIS) commonly involves excision, radiotherapy, and hormonal therapy. Radiotherapy is employed for local control in breast conservation. Evidence is evolving for several radiotherapy techniques exist beyond standard whole-breast irradiation.
Latest:
Can Locoregional Therapies Be Used in Metastatic Gastroesophageal Cancers?As part of our coverage of the 2018 GI Cancers Symposium, we discussed the role of locoregional therapies for patients with metastatic esophageal and gastric cancers.
Latest:
Using Genetic Testing to Help Prevent Colon CancerIn this interview we discuss the role of genetic testing in patients with colon cancer.
Latest:
Approaching Use of CDK4/6 Inhibitors in Metastatic HR+, HER2- Breast CancerAn otherwise healthy 58-year-old woman with a history of breast cancer presents to the clinic with newly diagnosed metastatic disease; eventual abdominal CT showed a mass in the transverse colon with ascites and peritoneal nodularity. What is the best initial systemic treatment for her?
Latest:
Further Thoughts on Adjuvant Treatment for Older Breast Cancer PatientsThe adjuvant treatment of breast cancer is facing a challenging phase due to the increasing knowledge of breast cancer biology and consequent need to personalize treatments. Medical oncologists are asked to practice evidence-based medicine, but their approach is often based on results of trials conducted in extremely heterogeneous populations.
Latest:
Seeing Red: Anthracyclines for Breast CancerDr. Henderson provides a thoughtful perspective on an important question that many clinicians often consider: can we ditch anthracyclines in favor of other, more effective and/or less toxic chemotherapeutic agents?
Latest:
Efstathiou Discusses Impact of Niraparib Combo From MAGNITUDE in mCRPCEleni Efstathiou, MD, PhD, spoke about how results of the phase 3 MAGNITUDE trial, which examined the combination of niraparib with abiraterone acetate and prednisone, have the ability to change the standard of care in patients with metastatic castration-resistant prostate cancer.
Latest:
Implications of the New Face of Head and Neck CancerAlthough screening methods for HPV-OPSCC have not yet been developed, population-based prevention may be achievable through HPV vaccination, but only if concerted efforts are made to increase vaccine uptake in the United States.
Latest:
A Clinician’s Perspective on ASCO 2001: Going After the Epidermal Growth Factor ReceptorAmong the most exciting new anticancer products presented at the 2001 ASCO meeting were new drugs that block the epidermal growth factor receptor (EGFR). About 30% to 90% of carcinomas express high levels of EGFR. These include, among others, head and neck cancer, lung cancer, pancreatic cancer, colon cancer, breast cancer, ovarian cancer, and bladder cancer.
Latest:
How to Address Sexual Problems in Female Cancer PatientsSexual health is an important aspect of human life, and cancer does not (and should not) change that. Data suggest that issues related to sexual function are quite common among women treated for cancer. However, clinicians often spend little to no time on the topic.
Latest:
Endocrine Therapy for Premenopausal Hormone-Responsive Breast Cancer: What Is the Optimal Therapy?The breast cancer treatment landscape is changing, and the optimal adjuvant endocrine therapy for premenopausal women with hormone receptor (HR)-positive breast cancer is uncertain.
Latest:
Clinical Uses of RadiosurgeryRadiosurgery uses stereotactic targeting methods to precisely deliver highly focused, large doses of radiation to small intracranial tumors and arteriovenous malformations (AVMs). This article reviews the most common
Latest:
Recent Advances in Hormonal Therapy for Advanced Prostate CancerFor many years, prostate cancerhas been known to be sensitiveto androgens. Indeed, endocrinemanipulations aimed at the reductionof serum testosterone to below oraround the castrate range have beenthe mainstay in the management ofadvanced prostate cancer for the past60 years. Despite widespread testing,the advances with this treatment modalityfor prostate cancer over the pastseveral decades have been modest.Unfortunately, the answers to manyrelevant critical questions still lie inthe future. The limiting factor of hormonaltherapy is that a significant proportionof tumor cells are not affectedby androgen deprivation.
Latest:
Olverembatinib Combos May Be ‘Promising’ in Ph+ Acute Lymphoblastic LeukemiaCombining olverembatinib with blinatumomab appears to produce high complete molecular remission rates in patients with newly diagnosed, Philadelphia chromosome–positive acute lymphoblastic leukemia, says Elias Jabbour, MD.
Latest:
Radium-223 in Bone-Metastatic Prostate Cancer: Current Data and Future ProspectsThis article will describe the historic background of Ra-223; outline the clinical studies which led to phase III trials of this agent; highlight key results of these phase III studies; and explore possible future directions for use of Ra-223 and other alpha particles-both in prostate cancer and for management of other diseases.
Latest:
Management of Acute Promyelocytic Leukemia: Implications for Treatment of Other CancersThe article by Drs. Stein and Tallman is an excellent summary indicating that several different approaches may lead to the cure of acute promyelocytic leukemia (APL).
Latest:
The Sentinel Node in Colorectal CarcinomaThe role of sentinel lymph node identification has been investigated over the past decade in a variety of malignancies. It has become part of standard care for melanoma. Its role in breast cancer is evolving, but with the completion of two large randomized clinical trials, it will probably be added to the surgical armamentarium for the management of most breast cancers. Studies have been proposed or are under way to evaluate sentinel node mapping in head and neck cancer, penile and vulvar cancer, and gastrointestinal cancers.
Latest:
Biological Basis of Radiation SensitivityRecent studies have elucidated some of the molecular and cellular mechanisms that determine the sensitivity or resistance to ionizing radiation. These findings ultimately may be useful in devising new strategies to improve the
Latest:
Management of Heavy Chain Diseases: The Challenges of Biologic HeterogeneityIn the absence of a clear understanding of the underlying biologic heterogeneity, the etiology of the different heavy chain diseases (HCDs) should be taken into consideration when treatment decisions are made. Extrapolation from related conditions, such as aggressive lymphomas (in γ-HCD) and CLL (in μ-HCD), suggests that novel and targeted therapies may be effective in the management of these rare diseases.
Latest:
Whole-Body PET Imaging of Breast Cancer Characteristics to Improve Precision TreatmentHowever, it is becoming ever clearer that tumor characteristics can change during the course of disease. Given this change over time, other supporting techniques for guiding therapy would be of value. Molecular radionuclide imaging with positron emission tomography (PET) can potentially fulfill this need.
Latest:
Outline of Oncology TherapeuticsOutline of Oncology Therapeutics is a well-written, concise, and up-to-date book providing detailed descriptions of a variety of medications and issues important to the overall care and treatment of patients with cancer. Oncology practice today
Latest:
Persistence of Lymphedema Reduction After Noninvasive Complex Lymphedema TherapySecondary lymphedema is quite prevalent in cancer patients who require lymph node dissection for staging and/or treatment of their disease. Chronic lymphedema may arise shortly after surgical intervention or months to years afterward. The tendency of chronic lymphedema is to worsen over time.
Latest:
New Combinations With Epirubicin in Advanced Breast CancerSeveral trials have shown that anthracyclines and taxanes can be combined to achieve response rates ranging from 70% to 90%, with complete responses ranging from 19% to 41%. In an attempt to increase the activity while
Latest:
PARP Inhibitors: The Cornerstone of DNA Repair–Targeted TherapiesPARP inhibitors are an active, novel, and exciting class of anticancer agents. They have shown clear patient benefit in gBRCA, HR-deficient, and other ovarian cancers.
